



**Universiteit
Leiden**
The Netherlands

Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study

Lindstrom, S.; Germain, M.; Crous-Bou, M.; Smith, E.N.; Morange, P.E.; Vlieg, A.V.; ... ; INVENT Consortium

Citation

Lindstrom, S., Germain, M., Crous-Bou, M., Smith, E. N., Morange, P. E., Vlieg, A. V., ... Kabrhel, C. (2017). Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study. *Human Genetics*, 136(7), 897-902. doi:10.1007/s00439-017-1811-x

Version: Not Applicable (or Unknown)
License: [Leiden University Non-exclusive license](#)
Downloaded from: <https://hdl.handle.net/1887/116526>

Note: To cite this publication please use the final published version (if applicable).



HHS Public Access

Author manuscript

Hum Genet. Author manuscript; available in PMC 2018 July 01.

Published in final edited form as:

Hum Genet. 2017 July ; 136(7): 897–902. doi:10.1007/s00439-017-1811-x.

Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study

Sara Lindström¹, Marine Germain^{2,3}, Marta Crous-Bou^{4,5}, Erin N. Smith^{6,7}, Pierre-Emmanuel Morange⁸, Astrid van Hylckama Vlieg⁹, Hugoline G. de Haan⁹, Daniel Chasman^{10,11}, Paul Ridker^{10,11}, Jennifer Brody¹², Mariza de Andrade¹³, John A Heit¹⁴, Weihong Tang¹⁵, Immaculata DeVivo^{4,5}, Francine Grodstein⁴, Nicholas L. Smith^{1,16,17}, David Tregouet^{2,3}, and Christopher Kabrhel^{11,18} for the INVENT Consortium

¹Department of Epidemiology, University of Washington, Seattle WA, USA ²Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Team Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France ³ICAN Institute for Cardiometabolism and Nutrition, Paris, France ⁴Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA ⁵Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA ⁶Department of Pediatrics, Rady Children's Hospital, University of California, San Diego, La Jolla, CA, USA ⁷K.G. Jebsen Thrombosis Research and Expertise Centre (TREC), Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway ⁸INSERM, UMR_S1062, Nutrition Obesity and Risk of Thrombosis, Aix-Marseille University, Marseille, France ⁹Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands ¹⁰Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA USA ¹¹Harvard Medical School, Boston MA, USA ¹²Department of Medicine, University of Washington, Seattle WA, USA ¹³Biomedical Statistics and Informatics, Mayo Clinic and College of Medicine, Rochester, MN, USA ¹⁴Division of Cardiovascular Diseases, Mayo Clinic and College of Medicine, Rochester, MN, USA ¹⁵Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA ¹⁶Group Health Research Institute, Group Health Cooperative, Seattle WA USA ¹⁷Seattle Epidemiologic Research and Information Center, Department of Veterans Affairs Office of Research and Development, Seattle WA USA ¹⁸Department of Emergency Medicine, Massachusetts General Hospital, Boston MA, USA

Abstract

*Corresponding Author: Sara Lindström, Department of Epidemiology, University of Washington, Seattle, WA. saralind@uw.edu., Phone: +1-206-221-3148 ORCID: 0000-0002-7137-7281.

CONFLICT OF INTEREST

On behalf of all authors, the corresponding author states that there is no conflict of interest.

ETICAL APPROVAL

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

INFORMED CONSENT

All participating studies were approved by their respective institutional review board and informed consent was obtained from all individual participants in the study.

Observational studies have shown an association between obesity and venous thromboembolism (VTE) but it is not known if observed associations are causal, due to reverse causation or confounding bias. We conducted a Mendelian Randomization study of body mass index (BMI) and VTE. We identified 95 single nucleotide polymorphisms (SNPs) that has been previously associated with BMI and assessed the association between genetically predicted high BMI and VTE leveraging data from a previously conducted GWAS within the INVENT consortium comprising a total of 7,507 VTE cases and 52,632 controls of European ancestry. Five BMI SNPs were associated with VTE at $P < 0.05$, with the strongest association seen for the *FTO* SNP rs1558902 (OR: 1.07, 95% CI: 1.02–1.12, $P = 0.005$). In addition, we observed a significant association between genetically predicted BMI and VTE (OR=1.59, 95% CI: 1.30–1.93 per standard deviation increase in BMI, $P = 5.8 \times 10^{-6}$). Our study provides evidence for a causal relationship between high BMI and risk of VTE. Reducing obesity levels will likely result in lower incidence in VTE.

Keywords

Obesity; venous thromboembolism; Mendelian randomization; SNP; association

INTRODUCTION

Venous thromboembolism (VTE) is the collective term for deep vein thrombosis (DVT) and its life-threatening complication pulmonary embolism (PE). Between 300,000–600,000 Americans are diagnosed with VTE every year, though VTE is under-diagnosed and accurate incidence data are difficult to estimate (Anderson et al. 2007; Heit et al. 2001; Hirsh and Hoak 1996). Further, it has been suggested that 60,000–100,000 Americans die of VTE annually. In addition, approximately a third of all VTE cases experience recurrence within 10 years (Beckman et al. 2010). The underlying mechanisms causing VTE remain, to a large extent, elusive. This is especially true for idiopathic (unprovoked) VTE. Known risk factors include oral contraception, menopausal hormone therapy, smoking, family history of VTE, and high body mass index (BMI) (Heit 2015). Data based on the National Hospital Discharge Survey between 1979 and 1999 showed that obese patients had a 2.5-fold (95% confidence interval [CI] = 2.49–2.51) risk to develop a DVT and 2.2-fold (95% CI = 2.20–2.23) risk to develop PE. Risks associated with obesity were highest in obese individuals less than 40 years old (Stein et al. 2005). Using data from the Nurses' Health Study, we previously showed that the association between BMI and VTE is linear and apparent even across a modest range (22.5–25 kg/m²) (Kabrhel et al. 2009). A drawback with observational studies is their limited ability to provide insights into causality. Establishing a causal relationship between a risk factor and disease requires circumventing issues of confounding, bias and reverse causation. Indeed, it is possible that observed BMI-VTE associations have been confounded by other risk factors that were not captured appropriately, including smoking habits, dietary habits, physical ability/activity or other underlying medical conditions. Further, observed BMI-VTE associations might also have been subject to reverse causation if individuals diagnosed with VTE have less physical ability leading to increased BMI. Mendelian Randomization (MR) is an approach that utilizes robust genetic predictors of risk factors to assess causal associations between risk factors and diseases (Davey Smith and

Hemani 2014). As inherited genetic variation is determined at conception and is in general not vulnerable to confounding, it represents a powerful tool for assessing causal relationships. Here, we leverage information from a recent genome-wide association study (GWAS) of BMI (Locke et al. 2015) to explore the causal relationship between obesity and VTE. We assessed the associations of 95 BMI single nucleotide polymorphisms (SNPs) in a VTE study comprising 7,507 cases and 52,632 controls (Germain et al. 2015).

MATERIAL AND METHODS

GWAS of VTE

To assess whether a genetically predicted BMI is associated with VTE, we used data from a recent GWAS of VTE within the INVENT consortium. Details about the GWAS design and participating studies have been published previously (Germain et al. 2015) and can be found in Supplementary Table 1. In total, 7,507 VTE cases and 52,632 controls from 12 studies were included. Study participants were European-ancestry adults in two French case-control studies, two Dutch case-control studies, and four cohort and four case-control studies from the United States. In all studies, VTE (PE or DVT) was objectively diagnosed by physicians using different techniques including compression venous duplex ultrasonography, computed tomography, Doppler ultrasound, impedance plethysmography, magnetic resonance, venography, pulmonary angiography, and ventilation/perfusion lung scan. VTE events related to cancer, autoimmune disorders, or natural anticoagulant inhibitor deficiencies (protein C, protein S, antithrombin) were excluded in most studies. All participating studies were approved by their respective institutional review board and informed consent was obtained from studied individuals. Genotyping arrays differed between studies (Germain et al. 2015). Each study was imputed using the 1000 Genomes phase I, version 3 reference dataset. Association analyses were performed separately in each study using logistic or Cox-proportional regression analyses adjusted for study-specific covariates. Results were then combined using fixed-effects meta-analysis. We only included SNPs with a minor allele frequency (MAF) >0.005 and with an imputation quality score (r^2) >0.3 in all 12 studies.

Identification of SNPs associated with BMI

We conducted a literature search to identify and extract information for SNPs that were associated with BMI on a genome-wide significant level ($P < 5 \times 10^{-8}$) in the largest GWAS to date. We identified 97 SNPs associated with BMI (Locke et al. 2015) (Supplementary Table 2). Of those 97 SNPs, 77 reached genome-wide significance in European ancestry populations only (European ancestry-specific P -values for the 20 remaining SNPs ranged between 6.0×10^{-8} and 6.1×10^{-6}). BMI SNPs rs11057405, rs2245368 and rs7239883 were not assessed in the INVENT VTE GWAS. We replaced rs7239883 with rs4569374 ($r^2=1.0$ in 1,000 Genomes CEU population), but we could not identify any proxies for the other two SNPs and they were therefore excluded from the analysis. For all identified SNPs, we obtained information about the effect allele, trait-specific association estimates and standard errors from the original publications. We then extracted VTE-specific effect estimates and P -values from the INVENT GWAS for each of the 95 SNPs.

Statistical Analysis

Since we do not have access to individual-level GWAS data in the VTE GWAS, we leverage recently developed methods to obtain an estimate of the causal effect of BMI on VTE. Specifically, we conducted 2-sample MR analyses to estimate the association between BMI and VTE using summary genetic association statistics, as described previously (Burgess et al. 2013). The ratio estimate ($\hat{\beta}$) of the effect of BMI (X) on VTE (Y) using genetic variants

$k=1, \dots, K$ (here, $K=95$) can be calculated as
$$\hat{\beta} = \frac{\sum_k X_k Y_k \sigma_{Y_k}^{-2}}{\sum_k X_k^2 \sigma_{Y_k}^{-2}}$$
 where X_k is the per-allele effect of SNP k on BMI, Y_k is the per-allele change in the log odds ratio for VTE for SNP k , and σ_{Y_k} is the standard error for Y_k . The standard error for $\hat{\beta}$ is given by:

$$se(\hat{\beta}) = \sqrt{\frac{1}{\sum_k X_k^2 \sigma_{Y_k}^{-2}}}$$
 Under certain assumptions (VanderWeele et al. 2014), $\hat{\beta}$ can be interpreted as the causal log odds ratio of VTE associated with one standard deviation (s.d.) unit change in BMI. We conducted two sets of analyses, the first analysis including all 95 SNPs for which we had data and the second analysis only including SNPs ($n=75$) that had been found associated on genome-wide significant levels with adult BMI in European ancestry populations only. For both SNP sets, effect estimates for BMI were extracted from a European ancestry population. To explore if the effect of BMI SNPs on VTE is independent of known VTE genetic risk factors, we reran the individual SNP analysis conditioning on the known VT SNPs including *F5* rs6025, *F5* rs4524, *F11* rs2289252, *F11* rs2036914, *FGG* rs2066865, *ABO* rs8176645, *ABO* rs8176746, *ABO* rs2519093, *F2* rs1799963, *PROCR* rs867186 and *PROCR* rs6088735 (Germain et al. 2015). We then reran the MR analysis including the 95 SNPs that have been shown to be associated with BMI. A key assumption in MR analysis is that the instrumental variables (genetic variants) can only be associated with the outcome through the risk factor of interest (BMI) and not through some other pathway (so called pleiotropy). Therefore, we conducted sensitivity analyses using MR Egger regression (Bowden et al. 2015) to assess bias from directional pleiotropy. All P values are unadjusted for multiple testing.

RESULTS

We selected 97 SNPs that have been found to be associated with BMI on a genome-wide significant level in a metaanalysis including all ethnicities (Locke et al. 2015). Together these SNPs explain ~2.7% of the variation in BMI. We were able to include 95 SNPs in our MR analysis. Five SNPs were associated with VTE at $P < 0.05$, with the strongest association seen for the *FTO* SNP rs1558902 (OR: 1.07, 95% CI: 1.02–1.12, $P=0.005$, Supplementary Table 2). The plot of VTE effect sizes vs. BMI effect sizes is seen in Figure 1. The overall association between genetically predicted BMI and VTE was 1.59 per s.d. increase in BMI (95% CI: 1.30–1.93, $P=5.8 \times 10^{-6}$, Table 1). We reran the analysis including only the 75 SNPs found to be genome-wide significant in European ancestry only and observed a similar association (OR=1.58, 95% CI: 1.28–1.95 per S.D. increase in BMI, $P=2.02 \times 10^{(222)5}$, Table 1). To explore if the effect of BMI SNPs on VTE is independent of known VTE genetic risk factors, we reran the analysis conditioning on 11 known VTE SNPs. The overall association

between genetically predicted BMI (based on 95 BMI-related SNPs) and VTE remained unchanged (OR=1.62 per s.d. increase in BMI, 95% CI: 1.31, 2.00; $P=7.2\times 10^{-6}$). We further explored the potential impact of directional pleiotropy by conducting MR Egger regression to estimate the average directional pleiotropic effect across the SNPs and to estimate the causal effect of BMI after adjusting for potential directional pleiotropic effects. We found that the intercept from MR Egger regression was not significantly different from zero (-0.005 , 95% CI: -0.02 , 0.01 ; $P=0.43$) suggesting no directional pleiotropy. Further, the estimated causal effect estimated by MR Egger regression was larger in magnitude compared to the MR analysis (OR=1.90, 95% CI: 1.17, 3.08; $P=0.01$, Table 1).

DISCUSSION

We used a Mendelian Randomization approach to assess the causal relationship between BMI and VTE in a European ancestry population. Our results showed evidence for a causal association between higher BMI and VTE, lending support to previous observational studies. Among the SNPs we assessed, we observed the strongest association for the *FTO* locus. SNP rs1558902 has been estimated to explain 0.33% of the variation in adult BMI, which is almost three times as much as any other single SNP and interestingly, this is also the SNP that showed strongest association with VTE in this analysis. Due to its association with BMI, SNP rs1558902 has been assessed for association with multiple other traits and has been found to be associated with C-reactive protein (CRP) levels and HDL cholesterol (Ligthart et al. 2016). A correlated SNP, rs9939609 ($r\text{-sq}=0.92$), has been found to be associated with a plethora of traits including heart failure, type II diabetes, dyslipidemia, hypertension, metabolic syndrome, liver enzymes, fasting insulin, CRP and triglycerides (Fall et al. 2013).

In addition to its association with environmental risk factors like obesity, VTE has a strong genetic basis following a multifactorial inheritance model (Crous-Bou et al. 2016). Most of the identified genetic risk factors involve mutations in the clotting system, including: variants in factor V (e.g. the Factor V Leiden mutation), prothrombin (e.g. prothrombin 20210-A), fibrinogen gamma, antithrombin, protein C, protein S as well as genetic variations coding for blood group non-O. To explore if the observed association between genetically predicted BMI and VTE is independent of known VTE genetic risk factors, we reran the analysis using VTE SNP effects conditioned on 11 known VTE genetic variants. The association between genetically predicted BMI and VTE remained unchanged, arguing that the causal effect of BMI on VTE is independent from known VTE genetic risk markers.

There are several plausible biological mechanisms by which obesity causes VTE. At one level, the development of VTE depends on mechanical factors such as venous stasis. Obesity may decrease venous return of blood from the lower extremities thereby increasing the risk of both VTE and chronic venous insufficiency (Willenberg et al. 2010). Obesity is also correlated with low-grade chronic inflammation (Blokchin and Lentz 2013), and inflammatory markers (e.g. CRP and albumin) have been shown to modulate the relationship between BMI and VTE (Olson et al. 2014). Finally, obesity may lead to impaired fibrinolysis, as obese subjects have increased circulating levels of plasminogen activator inhibitor-1 (PAI-1) which inhibits the breakdown of clot (Ouchi et al. 2011; Shimomura et al. 1996). Based on recent

estimates, more than one-third of Americans are obese, and the population prevalence of obesity in western countries continues to rise. The most recent data reported by the Centers for Disease Control and Prevention suggest that 37.7% of adults in the United States were obese in 2013–2014. This is up from 30.5% in 1999–2000(Ogden et al. 2015). Simultaneously, the incidence of VTE has also been increasing. In 2009, the annual incidence of first-time VTE diagnosis (DVT or PE or both) was 133/100,000 individuals. This is up from 95/100,000 individuals in 1999(Heit et al. 2016). The increased incidence of VTE is multifactorial, and likely related to both increasing disease occurrence in the population and increased detection due to improvements in diagnostic technology. By demonstrating a causal relationship between obesity and VTE, our data provide support that rising prevalence of obesity may help explain the high prevalence of VTE. Moreover, to the extent that public health interventions can reduce the incidence of obesity, there may be an accompanying decrease in the incidence of VTE.

MR analysis is based on a few key assumptions: 1) valid association between SNPs and risk factors; 2) SNPs are not associated with any confounders between the risk factors and outcome; and 3) SNPs only affect the outcome through the risk factor of interest (no pleiotropic effects). For the first assumption, we only used SNPs that have shown to be associated with BMI on a genome-wide significant level. For the second assumption, the major potential confounder is population stratification. We believe this to be small since the VTE GWAS was conducted in European ancestry populations only and analyses were adjusted for population stratification through principal components as appropriate. Although we included BMI SNPs that reached genome-wide significance in a multi-ethnic metaanalysis, our results did not change when we restricted our analysis to SNPs that reached genome-wide significance in European ancestry populations. We assessed the validity of the third assumption by performing MR Egger regression and observed no evidence of directional pleiotropic effects that would have influenced our results. However, we note that MR Egger regression is valid under the assumption that the association between genetic variants and the exposure (here BMI) are independent of the direct effects the genetic variants have on the outcome (here VTE). This assumption is also known as the InSIDE assumption and would thus be violated if any pleiotropic effects act through a confounder of the BMI-VTE association. Further, we note that MR Egger regression is only sensitive to directional pleiotropy, thus it will not detect situations where several SNPs exhibit pleiotropy but in different directions, canceling out the “overall effect” of pleiotropy. In addition, compared to the 2-sample MR analysis that was primarily used here, MR Egger regression has less power to detect a true causal effect in the presence of balanced pleiotropy(Bowden et al. 2016). Since our outcome was binary, there is a possibility that adjustment for covariates in the VTE analysis (in our case, primarily sex and age) will affect the causal estimate asymptotically as the coefficients from logistic regression are non-collapsible (Burgess et al. 2016). However, this should not affect the validity of causal findings, provided that the instrumental variables are valid both marginally and conditionally on the covariates. A potential limitation of our study is the use of summary-level statistics rather than individual-level data which would have allowed us to explore casual relationships in subgroups such as: PE vs. DVT, smokers vs. non-smokers or women vs. men.

In conclusion, using data from the largest GWAS of VTE to date, we found evidence of a causal relationship between high BMI and risk of VTE. Fighting current increasing trends in obesity will most likely lead to a reduction of VTE incidence.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by National Health Lung and Blood Institute grants HL116854, HL43201, HL60739, HL68986, HL73410, HL74745, HL85251, HL107442, HL66261, HL83141, HL59367 and HL95080 and the National Human Genome Research Institute (HG04735). The Nurses' Health Study, Nurses' Health Study II and Health Professionals Follow up Study are supported by the National Cancer Institute (CA186107, CA176726, CA167552). The WGHS is supported by the National Heart, Lung, and Blood Institute (HL043851 and HL080467) and the National Cancer Institute (CA047988 and CA182913). This work was partially supported by the GenMed LABEX (ANR-10-LABX-0013) and the ICAN Institute for Cardiometabolism and Nutrition (ANR-10-IAHU-05) and an independent grant from the K.G. Jebsen Foundation in Norway.

References

- Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. *Am J Hematol.* 2007; 82:777–82. DOI: 10.1002/ajh.20983 [PubMed: 17626254]
- Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. *Am J Prev Med.* 2010; 38:S495–501. DOI: 10.1016/j.amepre.2009.12.017 [PubMed: 20331949]
- Blokhin I, Lentz SR. Mechanisms of thrombosis in obesity. *Curr Opin Hematol.* 2013; 20:437–44. DOI: 10.1097/MOH.0b013e3283634443 [PubMed: 23817170]
- Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015; 44:512–25. DOI: 10.1093/ije/dyv080 [PubMed: 26050253]
- Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I² statistic. *Int J Epidemiol.* 2016; doi: 10.1093/ije/dyw220
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genet Epidemiol.* 2013; 37:658–65. DOI: 10.1002/gepi.21758 [PubMed: 24114802]
- Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. *Stat Med.* 2016; 35:1880–906. DOI: 10.1002/sim.6835 [PubMed: 26661904]
- Crous-Bou M, Harrington LB, Kabrhel C. Environmental and Genetic Risk Factors Associated with Venous Thromboembolism. *Semin Thromb Hemost.* 2016; 42:808–820. DOI: 10.1055/s-0036-1592333 [PubMed: 27764878]
- Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet.* 2014; 23:R89–98. DOI: 10.1093/hmg/ddu328 [PubMed: 25064373]
- Fall T, Hagg S, Magi R, Ploner A, Fischer K, Horikoshi M, Sarin AP, Thorleifsson G, Ladenvall C, Kals M, Kuningas M, Draisma HH, Ried JS, van Zuydam NR, Huikari V, Mangino M, Sonestedt E, Benyamin B, Nelson CP, Rivera NV, Kristiansson K, Shen HY, Havulinna AS, Dehghan A, Donnelly LA, Kaakinen M, Nuotio ML, Robertson N, de Bruijn RF, Ikram MA, Amin N, Balmforth AJ, Braund PS, Doney AS, Doring A, Elliott P, Esko T, Franco OH, Gretarsdottir S, Hartikainen AL, Heikkila K, Herzig KH, Holm H, Hottenga JJ, Hypponen E, Illig T, Isaacs A, Isomaa B, Karssen LC, Kettunen J, Koenig W, Kuulasmaa K, Laatikainen T, Laitinen J, Lindgren C, Lyssenko V, Laara E, Rayner NW, Mannisto S, Pouta A, Rathmann W, Rivadeneira F,

- Ruokonen A, Savolainen MJ, Sijbrands EJ, Small KS, Smit JH, Steinthorsdottir V, Syvanen AC, Taanila A, Tobin MD, Uitterlinden AG, Willems SM, Willemsen G, Witteman J, Perola M, Evans A, Ferrieres J, Virtamo J, Kee F, Tregouet DA, Arveiler D, Amouyel P, Ferrario MM, Brambilla P, Hall AS, Heath AC, Madden PA, Martin NG, Montgomery GW, Whitfield JB, Julia A, Knekt P, Oostra B, van Duijn CM, Penninx BW, Smith GD, Kaprio J, Samani NJ, Gieger C, et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. *PLoS Med*. 2013; 10:e1001474.doi: 10.1371/journal.pmed.1001474 [PubMed: 23824655]
- Germain M, Chasman DI, de Haan H, Tang W, Lindstrom S, Weng LC, de Andrade M, de Visser MC, Wiggins KL, Suchon P, Saut N, Smadja DM, Le Gal G, van Hylckama Vlieg A, Di Narzo A, Hao K, Nelson CP, Rocanin-Arjo A, Folkersen L, Monajemi R, Rose LM, Brody JA, Slagboom C, E, Aissi D, Gagnon F, Deleuze JF, Deloukas P, Tzourio C, Dartigues JF, Berr C, Taylor KD, Civelek M, Eriksson P, Cardiogenics C, Psaty BM, Houwing-Duitermaat J, Goodall AH, Cambien F, Kraft P, Amouyel P, Samani NJ, Basu S, Ridker PM, Rosendaal FR, Kabrhel C, Folsom AR, Heit J, Reitsma PH, Tregouet DA, Smith NL, Morange PE. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. *Am J Hum Genet*. 2015; 96:532–42. DOI: 10.1016/j.ajhg.2015.01.019 [PubMed: 25772935]
- Heit JA. Epidemiology of venous thromboembolism. *Nat Rev Cardiol*. 2015; 12:464–74. DOI: 10.1038/nrcardio.2015.83 [PubMed: 26076949]
- Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, Melton LJ 3rd. The epidemiology of venous thromboembolism in the community. *Thromb Haemost*. 2001; 86:452–63. [PubMed: 11487036]
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. *J Thromb Thrombolysis*. 2016; 41:3–14. DOI: 10.1007/s11239-015-1311-6 [PubMed: 26780736]
- Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. A statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. *Circulation*. 1996; 93:2212–45. [PubMed: 8925592]
- Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA. Prospective study of BMI and the risk of pulmonary embolism in women. *Obesity (Silver Spring)*. 2009; 17:2040–6. DOI: 10.1038/oby.2009.92 [PubMed: 19373223]
- Ligthart S, Vaez A, Hsu YH, Inflammation Working Group of the CC. Pmi Wg XCP, LifeLines Cohort S, Stolk R, Uitterlinden AG, Hofman A, Alizadeh BZ, Franco OH, Dehghan A. Bivariate genome-wide association study identifies novel pleiotropic loci for lipids and inflammation. *BMC Genomics*. 2016; 17:443.doi: 10.1186/s12864-016-2712-4 [PubMed: 27286809]
- Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, Powell C, Vedantam S, Buchkovich ML, Yang J, Croteau-Chonka DC, Esko T, Fall T, Ferreira T, Gustafsson S, Kutalik Z, Luan J, Magi R, Randall JC, Winkler TW, Wood AR, Workalemahu T, Faul JD, Smith JA, Hua Zhao J, Zhao W, Chen J, Fehrmann R, Hedman AK, Karjalainen J, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bolton JL, Bragg-Gresham JL, Buyske S, Demirkan A, Deng G, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Goel A, Gong J, Jackson AU, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Mangino M, Mateo Leach I, Medina-Gomez C, Medland SE, Nalls MA, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Shungin D, Stancakova A, Strawbridge RJ, Ju Sung Y, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Isaacs A, Albrecht E, Arnlöv J, Arscott GM, Attwood AP, Bandinelli S, Barrett A, Bas IN, Bellis C, Bennett AJ, Berne C, Blagieva R, Bluher M, Bohringer S, Bonnycastle LL, Botcher Y, Boyd HA, Bruinenberg M, Caspersen IH, Ida Chen YD, Clarke R, Daw EW, de Craen AJ, Delgado G, Dimitriou M, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature*. 2015; 518:197–206. DOI: 10.1038/nature14177 [PubMed: 25673413]
- Ogden, CL., Carroll, MD., Fryar, CD., Flegal, KM. NCHS Data Brief. 2015. Prevalence of Obesity Among Adults and Youth: United States, 2011–2014; p. 1-8.
- Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, Folsom AR, Zakai NA. Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. *J Thromb Haemost*. 2014; 12:1993–2001. DOI: 10.1111/jth.12742 [PubMed: 25292154]

- Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. *Nat Rev Immunol.* 2011; 11:85–97. DOI: 10.1038/nri2921 [PubMed: 21252989]
- Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. *Nat Med.* 1996; 2:800–3. [PubMed: 8673927]
- Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. *Am J Med.* 2005; 118:978–80. DOI: 10.1016/j.amjmed.2005.03.012 [PubMed: 16164883]
- VanderWeele TJ, Tchetgen Tchetgen EJ, Cornelis M, Kraft P. Methodological challenges in mendelian randomization. *Epidemiology.* 2014; 25:427–35. DOI: 10.1097/EDE.0000000000000081 [PubMed: 24681576]
- Willenberg T, Schumacher A, Amann-Vesti B, Jacomella V, Thalhammer C, Diehm N, Baumgartner I, Husmann M. Impact of obesity on venous hemodynamics of the lower limbs. *J Vasc Surg.* 2010; 52:664–8. DOI: 10.1016/j.jvs.2010.04.023 [PubMed: 20576394]




Fig 1. SNP-specific VTE effect sizes (log(OR) per added allele) vs. BMI effect sizes (β per s.d.) for known BMI SNPs. Circles correspond to individual SNPs.

Table 1

Associations between genetically predicted BMI and VTE.

Association between genetically predicted BMI and VTE using 95 SNPs from multi-ethnic BMI meta-analysis	
OR (95% CI)	P
1.59 (1.30–1.93)	5.8×10^{-6}
Association between genetically predicted BMI and VTE using 75 SNPs from European ancestry BMI meta-analysis	
OR (95% CI)	P
1.58 (1.28–1.95)	2.0×10^{-5}
Association between genetically predicted BMI (95 SNPs) and VTE based on MR Egger regression	
OR (95% CI)	P
1.90 (1.17–3.08)	0.01

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript